September 13th 2024, 2:54pm
The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.
September 13th 2024, 2:52pm
The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.
September 9th 2024, 3:00pm
Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis.
September 6th 2024, 2:50pm
The discussion will cover the current CLL treatment landscape, including first-line and later-line options; the medical experts will review first-line treatments, approach to treatment selection, factors influencing recommendations, and strategies for shared decision-making with patients.
September 6th 2024, 2:13pm
Medical experts explain CLL’s slow progression and its impact on treatment timing, and they also discuss the watch-and-wait approach, patient concerns, and how to address anxiety about delaying treatment.
September 6th 2024, 1:00pm
Dr. Partow Kebriaei explains what patients can expect before, during and after an allogeneic stem cell transplant to treat acute lymphoblastic leukemia.
September 5th 2024, 7:00pm
For patients with MDS, close monitoring by doctors may help determine the appropriate timing to undergo stem cell transplants before the disease worsens.
August 30th 2024, 2:13pm
Jim Plotkin shares his personal experience with CLL, including his initial symptoms, the diagnostic process, challenges faced, and advice for patients with newly diagnosed CLL. Medical experts discuss their approach to explaining CLL to new patients and inquire about essential patient education resources.
August 30th 2024, 1:59pm
Medical experts provide an overview of chronic lymphocytic leukemia (CLL), including its typical symptoms and diagnostic process. They also will inquire about key prognostic factors and their impact on patient care.
August 29th 2024, 9:00pm
Patients who have a higher risk of head and neck cancer recurrence can expect more — and sooner — monitoring of their disease.
“Chillin’ Out” and Finding Our Cancer Community
Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
Illuminating Compassion in Cancer Care